Letters were sent about Arsenic Trioxide (Trisenox), Uptravi▼ (selexipag), DepoCyte (cytarabine), Cinryze▼ (C1 esterase inhibitor [human]), and Clexane (enoxaparin sodium).
In June 2017, the following letters were sent to relevant healthcare professionals:
Arsenic Trioxide (Trisenox) 1 mg/mL concentrate for solution for infusion: importation and over-labelling of United States (US) Trisenox stock as Teva UK interim supply
Uptravi▼ (selexipag): concomitant use with strong CYP2C8 inhibitors (eg, gemfibrozil) now contraindicated
Cinryze▼ (C1 esterase inhibitor [human]): recommendations to prescribers in view of a potential supply shortage
DepoCyte (cytarabine): follow-up on EU supply issue
Clexane (enoxaparin sodium): updates to strength expression, dose regimens in DVT/PE, use in patients with severe renal impairment
Article citation: Drug Safety Update volume 10 issue 12, July 2017: 4.
Published: 20 July 2017